Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia.

IF 3.8 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Biochemia Medica Pub Date : 2021-06-15 Epub Date: 2021-04-15 DOI:10.11613/BM.2021.020706
Jasna Lenicek Krleza, Renata Zrinski Topic, Vladimir Stevanovic, Amarela Lukic-Grlic, Irena Tabain, Zrinjka Misak, Goran Roic, Bernard Kaic, Dijana Mayer, Zeljka Hruskar, Ljubo Barbic, Tatjana Vilibic-Cavlek
{"title":"Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia.","authors":"Jasna Lenicek Krleza, Renata Zrinski Topic, Vladimir Stevanovic, Amarela Lukic-Grlic, Irena Tabain, Zrinjka Misak, Goran Roic, Bernard Kaic, Dijana Mayer, Zeljka Hruskar, Ljubo Barbic, Tatjana Vilibic-Cavlek","doi":"10.11613/BM.2021.020706","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The study aimed to investigate the prevalence and titres of anti-SARS-CoV-2 antibodies in children treated at the Children's Hospital Zagreb in the first and the second wave of the COVID-19 pandemic. Statistical significance of difference at two time points was done to determine how restrictive epidemiological measures and exposure of children to COVID-19 infection affect this prevalence in different age groups.</p><p><strong>Materials and methods: </strong>At the first time point (13th to 29th May 2020), 240 samples and in second time point (24th October to 23rd November 2020), 308 serum samples were tested for anti-SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA) and electrochemiluminescence immunoassay (ECLIA). Confirmation of results and titre determination was done using virus micro-neutralization test. Subjects were divided according to gender, age and epidemiological history.</p><p><strong>Results: </strong>Seroprevalence of anti-SARS-CoV-2 antibodies differs significantly in two time points (P = 0.010). In first time point 2.9% of seropositive children were determined and in second time point 8.4%. Statistically significant difference (P = 0.007) of seroprevalence between two time points was found only in a group of children aged 11-19 years. At the first time point, all seropositive children were asymptomatic with titre < 8. At the second time point, 69.2% seropositive children were asymptomatic with titre ≥ 8.</p><p><strong>Conclusions: </strong>The prevalence of anti-SARS-CoV-2 antibodies was significantly lower at the first time point than at the second time point. Values of virus micro-neutralization test showed that low titre in asymptomatic children was not protective at the first time point but in second time point all seropositive children had protective titre of anti-SARS-CoV-2 antibodies.</p>","PeriodicalId":9021,"journal":{"name":"Biochemia Medica","volume":"31 2","pages":"020706"},"PeriodicalIF":3.8000,"publicationDate":"2021-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047792/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemia Medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.11613/BM.2021.020706","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/4/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The study aimed to investigate the prevalence and titres of anti-SARS-CoV-2 antibodies in children treated at the Children's Hospital Zagreb in the first and the second wave of the COVID-19 pandemic. Statistical significance of difference at two time points was done to determine how restrictive epidemiological measures and exposure of children to COVID-19 infection affect this prevalence in different age groups.

Materials and methods: At the first time point (13th to 29th May 2020), 240 samples and in second time point (24th October to 23rd November 2020), 308 serum samples were tested for anti-SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA) and electrochemiluminescence immunoassay (ECLIA). Confirmation of results and titre determination was done using virus micro-neutralization test. Subjects were divided according to gender, age and epidemiological history.

Results: Seroprevalence of anti-SARS-CoV-2 antibodies differs significantly in two time points (P = 0.010). In first time point 2.9% of seropositive children were determined and in second time point 8.4%. Statistically significant difference (P = 0.007) of seroprevalence between two time points was found only in a group of children aged 11-19 years. At the first time point, all seropositive children were asymptomatic with titre < 8. At the second time point, 69.2% seropositive children were asymptomatic with titre ≥ 8.

Conclusions: The prevalence of anti-SARS-CoV-2 antibodies was significantly lower at the first time point than at the second time point. Values of virus micro-neutralization test showed that low titre in asymptomatic children was not protective at the first time point but in second time point all seropositive children had protective titre of anti-SARS-CoV-2 antibodies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
克罗地亚 COVID-19 最初和第二波大流行期间萨格勒布儿童医院儿童感染 SARS-CoV-2 的血清流行率。
简介该研究旨在调查第一波和第二波COVID-19大流行期间在萨格勒布儿童医院接受治疗的儿童中抗SARS-CoV-2抗体的流行率和滴度。对两个时间点的差异进行统计,以确定限制性流行病学措施和儿童接触 COVID-19 感染会如何影响不同年龄组的这一流行率:在第一个时间点(2020年5月13日至29日),240份样本;在第二个时间点(2020年10月24日至11月23日),308份血清样本通过酶联免疫吸附试验(ELISA)和电化学发光免疫试验(ECLIA)检测抗SARS-CoV-2抗体。结果确认和滴度测定采用病毒微量中和试验进行。受试者根据性别、年龄和流行病学史进行分类:结果:抗 SARS-CoV-2 抗体的血清流行率在两个时间点有显著差异(P = 0.010)。第一个时间点为 2.9%,第二个时间点为 8.4%。只有在 11-19 岁的儿童群体中,两个时间点之间的血清阳性率有明显的统计学差异(P = 0.007)。在第一个时间点,所有血清反应呈阳性的儿童均无症状,滴度小于 8。在第二个时间点,69.2%的血清阳性儿童无症状,滴度≥8:抗 SARS-CoV-2 抗体的流行率在第一时间点明显低于第二时间点。病毒微量中和试验结果表明,无症状儿童的低滴度抗体在第一时间点没有保护作用,但在第二时间点,所有血清阳性儿童的抗 SARS-CoV-2 抗体滴度都具有保护作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Biochemia Medica
Biochemia Medica 医学-医学实验技术
CiteScore
5.50
自引率
3.00%
发文量
70
审稿时长
>12 weeks
期刊介绍: Biochemia Medica is the official peer-reviewed journal of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Journal provides a wide coverage of research in all aspects of clinical chemistry and laboratory medicine. Following categories fit into the scope of the Journal: general clinical chemistry, haematology and haemostasis, molecular diagnostics and endocrinology. Development, validation and verification of analytical techniques and methods applicable to clinical chemistry and laboratory medicine are welcome as well as studies dealing with laboratory organization, automation and quality control. Journal publishes on a regular basis educative preanalytical case reports (Preanalytical mysteries), articles dealing with applied biostatistics (Lessons in biostatistics) and research integrity (Research integrity corner).
期刊最新文献
Quality assurance of add-on testing in plasma samples: stability limit for 29 biochemical analytes Two cases with discrepancy in the quantitative cytological assessment of cerebrospinal fluid in neonatal samples using light microscopy in comparison with Sysmex XN-1000 Common P-glycoprotein () polymorphisms do not seem to be associated with the risk of rivaroxaban-related bleeding events: Preliminary data CLSI-based verification and establishment of reference intervals for common biochemical assays in Croatian newborns Prediction interval: A powerful statistical tool for monitoring patients and analytical systems
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1